ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 1426 • 2018 ACR/ARHP Annual Meeting

    The Utilization of S100 Proteins Testing in Pediatric Rheumatology Patients in a Tertiary Care Institution and Implications for Care

    Najla Aljaberi1, Angela Merritt2, Alexei Grom1, Grant Schulert3, Jennifer L. Huggins4, Michael Henrickson5 and Hermine I. Brunner1, 1Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Pediatric Rheumatology, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Rheumatology, Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 4Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 5Cincinnati Children’s Medical Center, Cincinnati, OH

    Background/Purpose: S100 proteins are calcium-binding proteins of increasing value as biomarkers in various inflammatory conditions (e.g. autoinflammatory diseases, vasculitides, inflammatory bowel disease). The two highly…
  • Abstract Number: 1973 • 2018 ACR/ARHP Annual Meeting

    Leveraging Publicly Available Gene Expression Data and Applying Machine Learning to Identify Novel Biomarkers for Rheumatoid Arthritis

    Dmitry Rychkov1, Marina Sirota2 and Cindy Lin3, 1Institute for Computational Health Sciences, University of Calfornia, San Francisco, San Francisco, CA, 2Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA, 3Stanford, Stanford, CA

    Background/Purpose: Diagnosis and monitoring the disease progression of RA is challenging requiring a combination of imaging techniques and blood tests. There is currently no biochemical…
  • Abstract Number: 2690 • 2018 ACR/ARHP Annual Meeting

    Potential Markers of Skin Involvement in Systemic Sclerosis

    Radim Becvar1, Hana Storkanova2, Barbora Sumova1, Maja Spiritovic1, Sabina Oreska2, Ladislav Šenolt1 and Michal Tomcik2, 1Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, 2Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Skin fibrosis is a hallmark of systemic sclerosis (SSc). There are no widely accepted biomarkers of skin involvement in this condition. Several serum or…
  • Abstract Number: 583 • 2018 ACR/ARHP Annual Meeting

    Identification of a Protein Profile Useful to Predict Response to Methotrexate in Early Rheumatoid Arthritis Patients

    Cristina Ruiz-Romero1, Florencia Picchi2, Lucia González2, Rebecca Hands3, Valentina Calamia2, Patricia Fernández4, Maria Camacho2, Rocío Paz2, Conrad Bessant5, Costantino Pitzalis3 and Francisco J Blanco6, 1Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, 2Rheumatology Research Group, Proteomics Unit-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, 3Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 4Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, 5School of Biological and Chemical Sciences, Queen Mary University of London, London, United Kingdom, 6Rheumatology Divison, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain

    Background/Purpose: Among the best known disease-modifying antirheumatic drugs, Methotrexate (MTX) is one of the most effective and widely used medications. It is used as a…
  • Abstract Number: 1042 • 2018 ACR/ARHP Annual Meeting

    Development of a Neo-Epitope Specific Assay for Serological Assessment of Type X Collagen Degradation and Its Potential Diagnostic Value for Knee Osteoarthritis

    Yi He1, Tina Manon-Jensen2, Lars Arendt-Nielsen3,4, Kristian Petersen3, Thorbjørn Gantzel5, Jonathan Samuels6, Steven B. Abramson7, Morten A. Karsdal8, Mukundan Attur9 and Anne C. Bay-Jensen8, 1Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 2Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 3Department of Health Science and Technology, Aalborg University, Aalborg, Denmark, 4C4Pain, Aalborg, Denmark, 5cOrthopedic Surgery Unit, Gentofte Hospital, Hellerup, Denmark, 6Department of Medicine, Divison of Rheumatology, NYU Langone Health, New York, NY, 7Dept of Medicine, NYU Langone Health, New York, NY, 8Nordic Bioscience, Herlev, Denmark, 9Rheumatology Research, NYU Langone Orthopedic Hospital, New York, NY

    Background/Purpose: Phenotypic changes of chondrocytes toward hypertrophy might be fundamental in the pathogenesis of OA, of which type X collagen is a well-known marker. The…
  • Abstract Number: 1442 • 2018 ACR/ARHP Annual Meeting

    Differential Chemical Isotope Labeling Liquid Chromatography Mass Spectrometry and a Universal Metabolome Standard Reveals a Metabolome Profile with Consistent Accuracy for Rheumatoid Arthritis

    Walter P. Maksymowych1, Xiaohang Wang2, Joel Paschke1, Rana Dadashova1, Edna Hutchings1 and Liang Li2, 1CaRE Arthritis, Edmonton, AB, Canada, 2Chemistry, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) is hampered by suboptimal accuracy of currently available serological biomarkers. Recent advancements in metabolomic profiling include dansylation liquid…
  • Abstract Number: 1983 • 2018 ACR/ARHP Annual Meeting

    Mutations Associated with Clonal Hematopoiesis of Indeterminate Potential Are Found in Peripheral Blood and Synovial Fluid Macrophages from Patients with Rheumatoid and Psoriatic Arthritis

    Maria De Santis1, Matteo Zampini2, Natasa Isailovic1, Elena Generali1, Giacomo Maria Guidelli1, Matteo Della Porta2 and Carlo Selmi1,3, 1Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, 2Oncology and Hematology Unit, Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy, 3BIOMETRA Department, University of Milan, Milan, Italy

    Background/Purpose: Myeloidmutations commonly associated to neoplasia in patients who do not meet the diagnostic criteria for myelodysplastic syndrome are coined as clonal hematopoiesis of indeterminate…
  • Abstract Number: 2775 • 2018 ACR/ARHP Annual Meeting

    Neutrophil to Lymphocyte Ratio Predicts Glucocorticoid Resistance in Polymyalgia Rheumatica

    Claire Owen1,2, Christopher McMaster2, David Liew1,2, Jessica Leung1,2, Andrew Scott3,4,5 and Russell Buchanan2,6, 1Medicine, University of Melbourne, Parkville VIC, Australia, 2Rheumatology, Austin Health, Heidelberg VIC, Australia, 3Medicine, University of Melbourne, Heidelberg VIC, Australia, 4Molecular Imaging and Therapy, Austin Health, Heidelberg VIC, Australia, 5Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg VIC, Australia, 6Medicine, University of Melbourne, Parkville, Australia

    Background/Purpose: Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have been demonstrated to correlate with disease activity and predict treatment response in…
  • Abstract Number: 584 • 2018 ACR/ARHP Annual Meeting

    Changes in CD4+ T and B Cell Profile As Indicator of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis

    Borja Hernández-Breijo1,2, Israel Gañán-Nieto3, Cristina Sobrino3, Victoria Navarro-Compán1, Ana Martínez1,2, Carlota García-Hoz3, Javier Bachiller3, María Gema Bonilla Hernán1,4, Garbiñe Roy5, Mónica Vázquez3, Alejandro Balsa1,6, Luisa María Villar3, Dora Pascual-Salcedo1, Eulalia Rodríguez-Martín3 and Chamaida Plasencia1,4, 1Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, 2Immunology. La Paz University Hospital, Madrid, Spain, 3Immuno-Rheumatology research group, IRYCIS. Ramón y Cajal University Hospital, Madrid, Spain, 4Rheumatology, La Paz University Hospital, Madrid, Spain, 5Immunology. Ramón y Cajal University Hospital and IRYCIS, Madrid, Spain, 6Hospital Universitario La Paz, Madrid, Spain

    Background/Purpose: TNF inhibitors (TNFi) are widely used for the treatment of rheumatoid arthritis (RA). This study aims to analyse the profile of peripheral blood mononuclear…
  • Abstract Number: 1049 • 2018 ACR/ARHP Annual Meeting

    Optical Biomarkers for the Early Diagnosis of Osteoarthritis

    Paula Casal Beiroa1,2, Elena F. Burguera2,3,4, Tamara Hermida-Gómez2,3,4, Noa Goyanes5, Natividad Oreiro4,6, Pío González7, Francisco J Blanco8 and Joana Magalhaes2,4,9, 1Unidad de Medicina Regenerativa. Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC). CHUAC. SERGAS., A Coruña, Spain, 2Centro de Investigaciones Científicas Avanzadas (CICA), Universidad de A Coruña (UDC)., a coruña, Spain, 3Unidad de Medicina Regenerativa, Grupo de Investigación en Reumatología, Agrupación Estratégica CICA-INIBIC, Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade de A Coruña (UDC), A Coruña, Spain, 4Centro de Investigación Biomédica en Red (CIBER), madrid, Spain, 5Centro de Investigaciones Científicas Avanzadas (CICA), Universidad de A Coruña (UDC)., A Coruña, Spain, 6Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña. España, A Coruna, Spain, 7Grupo de Nuevos Materiales. Departamento de Física Aplicada. Universidad de Vigo., Vigo, Spain, 8Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Universidade de A Coruña (UDC), A Coruña, Spain, 9Unidad de Medicina Regenerativa. Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC). CHUAC. SERGAS., a coruña, Spain

    Background/Purpose: Osteoarthritis (OA) is a rheumatic disease characterized by articular cartilage degradation. On its early stages, OA is asymptomatic and its current gold-standard diagnosis (X-Rays),…
  • Abstract Number: 1454 • 2018 ACR/ARHP Annual Meeting

    Levels of 14-3-3eta Are an Independent Predictor of Long-Term Radiographic Erosive Progression and of Short-Term Rapid Radiographic Erosive Progression in Patients with Inflammatory Polyarthritis

    Gilles Boire1, Nathalie Carrier2, Artur J deBrum Fernandes3, Patrick Liang1, Ariel Masetto4, Sophie Roux4, Norma K Biln5, Yuan Gui5, Jane Savill5, Sara Michienzi5 and Walter P. Maksymowych6, 1Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, 2Centre intégré universitaire de santé et de services sociaux de l'Estrie -Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, 3Medicine, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, 4Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, 5Augurex Life Sciences Corp, Vancouver, BC, Canada, 6Department of Medicine, CaRE Arthritis and University of Alberta, Edmonton, Canada, Edmonton, AB, Canada

    Background/Purpose: Our objective is to examine the additional contribution of 14-3-3η levels to known predictors of radiographic progression in inflammatory polyarthritis, both over several years…
  • Abstract Number: 1998 • 2018 ACR/ARHP Annual Meeting

    Autophagy-Related Molecules Detected in Blood and Cartilage Are Biomarkers of Joint Damage in OA

    Beatriz Carames1, Irene Lorenzo Gomez1, Jose Antonio Pinto Tasende2, Natividad Oreiro Villar2 and Francisco J Blanco1, 1Cartilage Biology Group, Rheumatology Division, INIBIC-CHUAC, A Coruña, A Coruña, Spain, 2Clinical Rheumatology Division, Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña, A Coruña, Spain

    Background/Purpose: In osteoarthritis (OA), defects in cellular homeostasis, and in particular in autophagy, are evident and precede joint damage. We have shown that there is…
  • Abstract Number: 2816 • 2018 ACR/ARHP Annual Meeting

    Development of a Microrna Panel for Predicting Coronary Atherosclerosis in Rheumatoid Arthritis

    Michelle J. Ormseth1, Joseph F. Solus1, Quanhu Sheng1, Fei Ye1, Yan Guo1, Qiong Wu1, Annette M. Oeser1, Ryan Allen1, Paolo Raggi2, Kasey Vickers1 and C Michael Stein1, 1Vanderbilt University Medical Center, Nashville, TN, 2University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Small noncoding RNAs (sRNAs), such as microRNAs (miRNAs), regulate gene expression and can be used as biomarkers of disease. Patients with rheumatoid arthritis (RA)…
  • Abstract Number: 594 • 2018 ACR/ARHP Annual Meeting

    Identification of Tocilizumab Treated RA Patients, Whom Are Not Likely to Show Long-Term Clinical Benefit; Reanalysis of the Biomarker Sub-Study of LITHE

    Anne C. Bay-Jensen1, Christian S. Thudium1, Claus Christiansen2 and Morten A. Karsdal1, 1Nordic Bioscience, Herlev, Denmark, 2Nordic Bioscience, Clinical Development, Herlev, Denmark

    Background/Purpose: Tocilizumab, anti-interleukin 6 receptor (IL-6R) therapy, is an effective treatment of rheumatoid arthritis (RA). However, a significant amount of patients do not respond adequately…
  • Abstract Number: 1064 • 2018 ACR/ARHP Annual Meeting

    Identification of a Panel of Circulating Proteins Associated to Synovial Pathotypes in Early Rheumatoid Arthritis Patients

    Cristina Ruiz-Romero1, Florencia Picchi2, Patricia Fernández3, Lucia González2, Rebecca Hands4, Valentina Calamia2, Maria Camacho2, Conrad Bessant5, Costantino Pitzalis4 and Francisco J Blanco6, 1Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, 2Rheumatology Research Group, Proteomics Unit-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, 3Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, 4Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 5School of Biological and Chemical Sciences, Queen Mary University of London, London, United Kingdom, 6Rheumatology Divison, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is characterized by high clinical variability and an underlying cellular and molecular heterogeneity. Efforts to find tools for the classification of…
  • « Previous Page
  • 1
  • …
  • 55
  • 56
  • 57
  • 58
  • 59
  • …
  • 96
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology